386297-97-8
Chemical Structure
DPA-713
- CAS No.: 386297-97-8
- Formula:C21H26N4O2
- Molecular Weight:366.47
IUPAC Name: N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide
InChIKey: ILZWUAWCTNWSFZ-UHFFFAOYSA-N
SMILES: O=C(N(CC)CC)CC=1C(=NN2C1N=C(C=C2C)C)C=3C=CC(OC)=CC3
Biological Activity: DPA-713 is a blood-brain barrier-permeable, specific translocator protein (TSPO) ligand. DPA-713 binds exclusively to TSPO without interacting with central benzodiazepine receptors; its binding can be competitively displaced by excess unlabeled TSPO ligands. After 11C labeling, DPA-713 enables sensitive quantitative analysis of TSPO expression associated with microglial activation, allowing differentiation between normal and pathological brain tissues. DPA-713 can be used in studies related to neuroinflammation, neurodegenerative diseases, and recently onset schizophrenia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DPA-713 | 99.86% | DPA-713 is a blood-brain barrier-permeable, specific translocator protein (TSPO) ligand. DPA-713 binds exclusively to TSPO without interacting with central benzodiazepine receptors; its binding can be competitively displaced by excess unlabeled TSPO ligands. After 11C labeling, DPA-713 enables sensitive quantitative analysis of TSPO expression associated with microglial activation, allowing differentiation between normal and pathological brain tissues. DPA-713 can be used in studies related to neuroinflammation, neurodegenerative diseases, and recently onset schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Boutin H, et al. 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007 Apr;48(4):573-81. [Content Brief]
- [2]. Endres CJ, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009 Aug;50(8):1276-82. [Content Brief]
- [3]. Coughlin JM, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Translational psychiatry. 2016 Apr 12;6(4):e777. [Content Brief]
